Which parameters predict the beneficial effect of GnRHa treatment on height in girls with central precocious puberty?

VURALLI KARAOĞLAN D., Gonc N. E., ÖZÖN Z. A., KANDEMİR N., ALİKAŞİFOĞLU A.

CLINICAL ENDOCRINOLOGY, cilt.94, sa.5, ss.804-810, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 94 Sayı: 5
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1111/cen.14420
  • Dergi Adı: CLINICAL ENDOCRINOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, CAB Abstracts, EMBASE, Gender Studies Database, MEDLINE
  • Sayfa Sayıları: ss.804-810
  • Anahtar Kelimeler: body height, bone age measurement, central precocious puberty, child, gonadotropin&#8208, releasing hormone, idiopathic sexual precocity, leuprolide
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Objective Data about GnRHa on adult height in girls with central precocious puberty (CPP) have shown variable results, ranging from improvement of growth prognosis to lack of any benefit. This study was designed to delineate the criteria to decide which girls with idiopathic CPP (iCPP) will have a height benefit from GnRHa treatment.